-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-08-30
ILMN:NGS-Illumina Inc. (USD)
EQUITY | N/A | Nasdaq Global Select
Last Closing
USD 131.4Change
0.00 (0.00)%Market Cap
USD 19.79BVolume
0.97MN/A
Verdict
Values as of: 2024-08-30
EQUITY | N/A | Nasdaq Global Select
Last Closing
USD 131.4Change
0.00 (0.00)%Market Cap
USD 19.79BVolume
0.97MN/A
Verdict
Illumina Inc provides sequencing-and array-based solutions for genetic analysis. Its products enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response.
Company Website : http://www.illumina.com
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
ATCOL | Atlas Corp |
N/A |
USD 3.36B |
OPINL | Office Properties Income Trust |
-0.01 (-0.08%) |
USD 1.21B |
PLMIW | Plum Acquisition Corp. I |
+0.05 (+99.80%) |
USD 0.39B |
PLMIU | Plum Acquisition I Corp Unit |
+1.19 (+12.27%) |
USD 0.39B |
LCAPW | Lionheart Acquisition Corporat.. |
N/A |
USD 0.29B |
GBRGW | Goldenbridge Acquisition Limit.. |
+0.01 (+3.61%) |
USD 0.06B |
GLACR | Global Lights Acquisition Corp.. |
N/A |
N/A |
ADC-PA | Agree Realty Corporation |
+0.02 (+0.10%) |
N/A |
FLYE | Fly-E Group, Inc. Common Stock |
-0.01 (-1.63%) |
N/A |
BRACR | Broad Capital Acquisition Corp.. |
N/A |
N/A |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
CURG:LSE | VanEck Genomics and Healt.. | 6.64 % | 0.00 % |
+0.21 (+1.41%) |
USD 6.97M |
BIS | ProShares UltraShort Nasd.. | 5.67 % | 0.95 % |
-0.46 (1.41%) |
USD 3.31M |
CURE:XETRA | VanEck Genomics and Healt.. | 5.36 % | 0.00 % |
+0.28 (+1.41%) |
N/A |
XGES:LSE | Xtrackers MSCI Genomic He.. | 4.12 % | 0.00 % |
+0.23 (+1.41%) |
N/A |
BBH | VanEck Biotech ETF | 4.08 % | 0.35 % |
+1.73 (+1.41%) |
USD 0.45B |
EDOC | Global X Telemedicine & D.. | 4.07 % | 0.00 % |
+0.14 (+1.41%) |
USD 0.04B |
EDOC:LSE | Global X Telemedicine & D.. | 3.92 % | 0.00 % |
+0.18 (+1.41%) |
USD 3.76M |
EDOG:LSE | Global X Telemedicine & D.. | 3.91 % | 0.00 % |
+0.10 (+1.41%) |
USD 0.23M |
XGEN:XETRA | Xtrackers MSCI Genomic He.. | 3.84 % | 0.00 % |
+0.31 (+1.41%) |
N/A |
CDNA:CA | 2.74 % | 0.00 % |
N/A |
N/A | |
IBBQ | Invesco Nasdaq Biotechnol.. | 2.01 % | 0.00 % |
+0.39 (+1.41%) |
USD 0.04B |
QQXT | First Trust NASDAQ-100 Ex.. | 1.99 % | 0.60 % |
+0.83 (+1.41%) |
USD 0.13B |
2B70:F | iShares NASDAQ US Biotech.. | 1.96 % | 0.00 % |
N/A |
USD 0.52B |
2B70:XETRA | iShares Nasdaq US Biotech.. | 1.96 % | 0.00 % |
+0.07 (+1.41%) |
USD 0.52B |
HTEC | Robo Global® Healthcare .. | 1.87 % | 0.00 % |
+0.32 (+1.41%) |
USD 0.06B |
ROBE:LSE | L&G ROBO Global Robotics .. | 1.84 % | 0.00 % |
+0.13 (+1.41%) |
USD 0.69B |
ROBG:LSE | L&G ROBO Global Robotics .. | 1.84 % | 0.00 % |
+15.75 (+1.41%) |
USD 0.69B |
ROBO:LSE | Legal & General UCITS ETF.. | 1.84 % | 0.00 % |
+0.38 (+1.41%) |
USD 0.69B |
IROB:XETRA | L&G ROBO Global Robotics .. | 1.84 % | 0.00 % |
+0.19 (+1.41%) |
USD 0.91B |
ROBO | Robo Global® Robotics an.. | 1.82 % | 0.00 % |
+0.36 (+1.41%) |
USD 1.12B |
ROBO | Robo Global® Robotics an.. | 1.82 % | 0.95 % |
+0.36 (+1.41%) |
USD 1.12B |
DOCG:LSE | L&G Healthcare Breakthrou.. | 1.82 % | 0.00 % |
+6.50 (+1.41%) |
USD 0.07B |
DOCT:LSE | L&G Healthcare Breakthrou.. | 1.81 % | 0.00 % |
+0.23 (+1.41%) |
USD 0.07B |
XMLH:F | Legal & General Ucits Etf.. | 1.77 % | 0.00 % |
-0.06 (1.41%) |
USD 0.07B |
DOCT:SW | L&G Healthcare Breakthrou.. | 1.77 % | 0.00 % |
+0.11 (+1.41%) |
USD 0.07B |
BTEC:SW | iShares Nasdaq US Biotech.. | 1.73 % | 0.00 % |
+0.11 (+1.41%) |
N/A |
ROBO:AU | ETFS ROBO Global Robotics.. | 1.71 % | 0.00 % |
+0.18 (+1.41%) |
USD 0.23B |
ROBO:SW | L&G ROBO Global Robotics .. | 1.70 % | 0.00 % |
+0.21 (+1.41%) |
N/A |
IJJ | iShares S&P Mid-Cap 400 V.. | 1.52 % | 0.25 % |
+2.23 (+1.41%) |
USD 7.40B |
BIB | ProShares Ultra Nasdaq Bi.. | 1.30 % | 0.95 % |
+2.09 (+1.41%) |
USD 0.09B |
QQEW | First Trust NASDAQ-100 Eq.. | 1.21 % | 0.60 % |
+0.98 (+1.41%) |
USD 1.93B |
QQEQ:CA | Invesco NASDAQ 100 Equal .. | 1.16 % | 0.00 % |
+0.30 (+1.41%) |
CAD 9.99M |
IJH | iShares Core S&P Mid-Cap .. | 0.74 % | 0.07 % |
+1.07 (+1.41%) |
USD 85.42B |
ZMID-F:CA | BMO S&P US Mid Cap Index .. | 0.70 % | 0.00 % |
N/A |
CAD 2.03M |
ZMID-U:CA | BMO S&P US Mid Cap Index .. | 0.70 % | 0.00 % |
N/A |
N/A |
SPY4:PA | SSgA SPDR S&P 400 US Mid .. | 0.69 % | 0.00 % |
+1.11 (+1.41%) |
USD 2.07B |
SPY4:SW | SPDR® S&P 400 US Mid Cap.. | 0.69 % | 0.00 % |
+0.16 (+1.41%) |
USD 2.08B |
SPX4:LSE | SPDR® S&P 400 US Mid Cap.. | 0.62 % | 0.00 % |
+0.90 (+1.41%) |
N/A |
EWSP:SW | iShares S&P 500 Equal Wei.. | 0.23 % | 0.00 % |
+0.11 (+1.41%) |
USD 1.65B |
ALFA | 0.00 % | 0.65 % |
N/A |
N/A | |
IBB | iShares Biotechnology ETF | 0.00 % | 0.47 % |
+2.25 (+1.41%) |
USD 7.71B |
IBCE | 0.00 % | 0.10 % |
N/A |
N/A | |
IBDD | 0.00 % | 0.10 % |
N/A |
N/A | |
IVOO | Vanguard S&P Mid-Cap 400 .. | 0.00 % | 0.15 % |
+1.86 (+1.41%) |
USD 2.12B |
IVOV | Vanguard S&P Mid-Cap 400 .. | 0.00 % | 0.20 % |
+1.74 (+1.41%) |
USD 0.88B |
MDY | SPDR® S&P MIDCAP 400 ETF.. | 0.00 % | 0.24 % |
+9.52 (+1.41%) |
USD 21.50B |
MDYV | SPDR® S&P 400 Mid Cap Va.. | 0.00 % | 0.15 % |
+1.47 (+1.41%) |
N/A |
PBE | Invesco Dynamic Biotechno.. | 0.00 % | 0.57 % |
+1.20 (+1.41%) |
N/A |
QQQE | Direxion NASDAQ-100 Equal.. | 0.00 % | 0.35 % |
+0.63 (+1.41%) |
USD 1.21B |
BTEC | 0.00 % | 0.42 % |
N/A |
N/A | |
ROBT | First Trust Nasdaq Artifi.. | 0.00 % | 0.65 % |
+0.46 (+1.41%) |
USD 0.42B |
BTEC:LSE | iShares Nasdaq US Biotech.. | 0.00 % | 0.00 % |
+0.12 (+1.41%) |
N/A |
BTEK:LSE | iShares Nasdaq US Biotech.. | 0.00 % | 0.00 % |
+0.06 (+1.41%) |
N/A |
BTEE:LSE | iShares Nasdaq US Biotech.. | 0.00 % | 0.00 % |
+0.11 (+1.41%) |
N/A |
ZBIO | 0.00 % | 0.95 % |
N/A |
N/A | |
SPY4:LSE | SPDR® S&P 400 US Mid Cap.. | 0.00 % | 0.00 % |
+1.73 (+1.41%) |
N/A |
SPY4:F | SSgA SPDR S&P 400 US Mid .. | 0.00 % | 0.00 % |
+1.18 (+1.41%) |
N/A |
SPY4:XETRA | SSgA SPDR S&P 400 US Mid .. | 0.00 % | 0.00 % |
+1.10 (+1.41%) |
USD 1.99B |
ZMID:CA | BMO S&P US Mid Cap Index .. | 0.00 % | 0.00 % |
+1.09 (+1.41%) |
N/A |
XMLH:XETRA | L&G Healthcare Breakthrou.. | 0.00 % | 0.00 % |
+0.12 (+1.41%) |
USD 0.07B |
BBIG:CA | 0.00 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (N/A) | Market Performance vs. Exchange (Nasdaq Global Select) | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 12 Months | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -14.95% | N/A | N/A | 21% | F | ||
Dividend Return | -14.95% | N/A | N/A | 21% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 33.51% | N/A | N/A | 55% | F | ||
Risk Adjusted Return | -44.60% | N/A | N/A | 19% | F | ||
Market Capitalization | 19.79B | N/A | N/A | N/A | N/A |
Ratio vs. Industry/Classification (N/A) | Ratio vs. Market (Nasdaq Global Select) | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
Market Value | |||||||
Price / Earning Ratio | 45.90 | N/A | N/A | ||||
Price/Book Ratio | N/A | N/A | N/A | ||||
Price / Cash Flow Ratio | N/A | N/A | N/A | ||||
Price/Free Cash Flow Ratio | N/A | N/A | N/A | ||||
Management Effectiveness | |||||||
Return on Equity | N/A | N/A | N/A | ||||
Return on Invested Capital | N/A | N/A | N/A | ||||
Return on Assets | N/A | N/A | N/A | ||||
Debt to Equity Ratio | N/A | N/A | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
There is nothing we particularly dislike